Goodrx Holdings, Inc. (GDRX) Stock Price & Analysis
Goodrx Holdings, Inc. (GDRX) rose 0.00% to USD 2.96 as of July 25, 2026 at 02:23 UTC, according to Nexqual real-time market data.
GDRX last closed at USD 2.96; the session ranged USD 2.84–2.96 on volume of 529,504 shares. Market capitalization is —, with a 52-week range of USD 1.77–5.81 (NMS). Source: Nexqual, July 25, 2026 at 02:23 UTC.
Key Statistics (as of July 25, 2026 at 02:23 UTC)
| Price | USD 2.96 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 2.96 |
| Open | USD 2.96 |
| Day Range | USD 2.84 – 2.96 |
| 52-Week Range | USD 1.77 – 5.81 |
| Volume | 529,504 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (GDRX)
Nexqual's technical model rates GDRX "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 02:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 52.43 (neutral) |
| vs SMA50 | Above (USD 2.81) |
| MACD | 0.06 (positive) |
From Goodrx Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Technology The key elements of our technology include: • Proprietary Pricing Engine: Our price ingestion technology enables us to link with multiple sources spanning the healthcare industry.
- Our proprietary technology enables us to aggregate prescription pricing data points from sources spanning the healthcare industry.
- Our broad set of long-term relationships across the industry, combined with our proprietary platform, allows us to present highly competitive prices to consumers.
- Our proprietary technology enables us to combine prices from multiple PBMs and other industry sources and display it on a single consumer interface.
Partnerships
- In 2025, we partnered with select pharmacies to offer our brand medication savings solution, RxSmartSaver+ , to their consumers for a monthly or annual fee. • Condition-Specific Subscriptions: We first launched condition-specific subscriptions in 2025.
- In 2025, we continued to grow our consumer direct pricing and announced a collaboration with a pharmaceutical manufacturer to offer eligible patients nationwide two of the most in-demand GLP-1 medications at a significantly lower cash price through our platform.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AMWL | American Well Corporation | USD 10.81 | ▼ 7.29% |
| FROG | JFrog Ltd. | USD 80.16 | ▲ 0.6% |
| ASAN | Asana, Inc. | USD 6.86 | ▼ 0.29% |
| NCNO | nCino, Inc. | USD 16.56 | ▼ 0.24% |
| GTM | ZoomInfo Technologies Inc. | USD 2.92 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:23 UTC. This page is informational and not investment advice.